Skip to main content

Table 1 Characteristics of human umbilical cord mesenchymal stem cells for treatments

From: Topical and intravenous administration of human umbilical cord mesenchymal stem cells in patients with diabetic foot ulcer and peripheral arterial disease: a phase I pilot study with a 3-year follow-up

Quality parameters

Results (n = 4 a)

Cell surface markers

 HLA-DR, mean ± SD (%)

1.0 ± 0.2

 CD79a/ CD19, mean ± SD (%)

0.8 ± 0.2

 CD45, mean ± SD (%)

1.5 ± 0.3

 CD34, mean ± SD (%)

1.3 ± 0.4

 CD14, mean ± SD (%)

1.1 ± 0.3

 CD105, mean ± SD (%)

98.4 ± 0.3

 CD90, mean ± SD (%)

98.7 ± 0.6

 CD73, mean ± SD (%)

97.3 ± 0.4

 Viability rate, mean ± SD (%)

98.2 ± 0.3

 Cell count, cells/ ml

(2.1 ± 0.1) × 107

Pathogen tests

 Anaerobic bacteria

Negative

 Aerobic bacteria

Negative

 Fungi

Negative

 Cytomegalovirus

Negative

 Human T-cell leukemia virus

Negative

 Mycoplasma

Negative

 Endotoxin

 < 0.5 EU/ ml

  1. ahUC-MSCs were provided in 4 batches
  2. HLA-DR human leukocyte antigen-DR, hUC-MSC human umbilical cord mesenchymal stem cell, SD standard deviation